BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14

• Press Releases

  Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS

  August 6, 2026

   · 

  4 min read
• Press Releases

  PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  August 6, 2026

   · 

  9 min read
• Press Releases

  Dispatch Bio Announces First Patient Dosed in Phase 1 Study of DISP-10, a Novel Investigational Immunotherapy, in Advanced Gastrointestinal (GI) Cancers

  August 6, 2026

   · 

  5 min read
• Press Releases

  Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

  August 6, 2026

   · 

  13 min read
• Press Releases

  PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

  August 6, 2026

   · 

  6 min read
• 

  Pipeline

  Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’

  Since stepping in as Sanofi’s CEO in April, Belén Garijo has launched a deep look at the pharma’s pipeline, reassessing assets based on “scientific merit” and potential for long-term value in the quest for a Dupixent follow-up.

  August 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Takeda’s narcolepsy nod opens orexin doors

  Orzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is “likely to reshape the treatment paradigm” for the condition, Jefferies told investors.

  August 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

  August 6, 2026

   · 

  7 min read
• Press Releases

  MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

  August 6, 2026

   · 

  2 min read
• Press Releases

  Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

  August 6, 2026

   · 

  1 min read